Trial Profile
Phase I Study of PF-00477736 With Gemcitabine In Patients With Advanced Solid Malignancies.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2012
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; PF 477736 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 19 Jul 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 12 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Apr 2011 Planned End Date changed from 1 Feb 2011 to 1 Apr 2011.